HYPIEND

Exposure to multiple endocrine disrupting chemicals is an environmental insult that interferes with the development and function of the endocrine system. This interaction is specially concerning in developmental stages of life, such as the perinatal period and puberty. Despite the current body of knowledge on endocrine disruptors actions on the endocrine system, a comprehensive, holistic understanding of the impact on the HP axis is still lacking. HYPIEND project aims to understand the effects of endocrine disruptors co-exposure in the function and epigenetic programming of the HP axis to delineate interventional strategies for minimizing exposure and consequences on the neuroendocrine system during the perinatal and pre-pubertal stages. To do that, a computational toxicology methodological framework will be built leveraging public data and state of the art data analysis techniques to define co-exposure patterns in target population. The resulting patterns will be evaluated in a sequential tiered approach consisting in cell-based screenings, Danio rerio models of HP axes, in vitro, in silico and in vivo models of placenta and blood brain barrier diffusion and new models of organoids-based organ-on-chip recapitulating the HP axis. Endocrine disruptors' effects on epigenetic programming will be evaluated in preclinical models of perinatal and early childhood. The knowledge generated in preclinical models will be applied in two multi-centre-controlled intervention studies intended to minimize exposure to endocrine disruptors in children in the perinatal and pre-puberty stages. HYPIEND outcomes will be novel approach methodologies based in in vitro and in silico models, non-invasive biomarkers of HP disruption by EDC and new intervention strategies to minimize EDC exposure in sensitive population. This project has received funding from the European Union’s Horizon Europe research and innovation programme: project num. 101137440.

Website

www.hypiend.eu

External link for HYPIEND

Industry

Public Health

Company size

51-200 employees

Type

Partnership

Founded

2024

Specialties

nutrition, endocrine disruptors, omic sciences, endocrinology, clinical medicine, toxicology, epigenetics, obstetrics, neuroendocrine, hypothalamus, computational toxicology, prepubertal children, preclinical models, organoids, and 1000 days